Cargando…

HIV-1 Phenotypic Reverse Transcriptase Inhibitor Drug Resistance Test Interpretation Is Not Dependent on the Subtype of the Virus Backbone

To date, the majority of HIV-1 phenotypic resistance testing has been performed with subtype B virus backbones (e.g. HXB2). However, the relevance of using this backbone to determine resistance in non-subtype B HIV-1 viruses still needs to be assessed. From 114 HIV-1 subtype C clinical samples (36 A...

Descripción completa

Detalles Bibliográficos
Autores principales: Bronze, Michelle, Steegen, Kim, Wallis, Carole L., De Wolf, Hans, Papathanasopoulos, Maria A., Van Houtte, Margriet, Stevens, Wendy S., de Wit, Tobias Rinke, Stuyver, Lieven J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3322145/
https://www.ncbi.nlm.nih.gov/pubmed/22496845
http://dx.doi.org/10.1371/journal.pone.0034708
_version_ 1782229036984958976
author Bronze, Michelle
Steegen, Kim
Wallis, Carole L.
De Wolf, Hans
Papathanasopoulos, Maria A.
Van Houtte, Margriet
Stevens, Wendy S.
de Wit, Tobias Rinke
Stuyver, Lieven J.
author_facet Bronze, Michelle
Steegen, Kim
Wallis, Carole L.
De Wolf, Hans
Papathanasopoulos, Maria A.
Van Houtte, Margriet
Stevens, Wendy S.
de Wit, Tobias Rinke
Stuyver, Lieven J.
author_sort Bronze, Michelle
collection PubMed
description To date, the majority of HIV-1 phenotypic resistance testing has been performed with subtype B virus backbones (e.g. HXB2). However, the relevance of using this backbone to determine resistance in non-subtype B HIV-1 viruses still needs to be assessed. From 114 HIV-1 subtype C clinical samples (36 ARV-naïve, 78 ARV-exposed), pol amplicons were produced and analyzed for phenotypic resistance using both a subtype B- and C-backbone in which the pol fragment was deleted. Phenotypic resistance was assessed in resulting recombinant virus stocks (RVS) for a series of antiretroviral drugs (ARV's) and expressed as fold change (FC), yielding 1660 FC comparisons. These Antivirogram® derived FC values were categorized as having resistant or sensitive susceptibility based on biological cut-off values (BCOs). The concordance between resistance calls obtained for the same clinical sample but derived from two different backbones (i.e. B and C) accounted for 86.1% (1429/1660) of the FC comparisons. However, when taking the assay variability into account, 95.8% (1590/1660) of the phenotypic data could be considered as being concordant with respect to their resistance call. No difference in the capacity to detect resistance associated with M184V, K103N and V106M mutations was noted between the two backbones. The following was concluded: (i) A high level of concordance was shown between the two backbone phenotypic resistance profiles; (ii) Assay variability is largely responsible for discordant results (i.e. for FC values close to BCO); (iii) Confidence intervals should be given around the BCO's, when assessing resistance in HIV-1 subtype C; (iv) No systematic resistance under- or overcalling of subtype C amplicons in the B-backbone was observed; (v) Virus backbone subtype sequence variability outside the pol region does not contribute to phenotypic FC values. In conclusion the HXB2 virus backbone remains an acceptable vector for phenotyping HIV-1 subtype C pol amplicons.
format Online
Article
Text
id pubmed-3322145
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-33221452012-04-11 HIV-1 Phenotypic Reverse Transcriptase Inhibitor Drug Resistance Test Interpretation Is Not Dependent on the Subtype of the Virus Backbone Bronze, Michelle Steegen, Kim Wallis, Carole L. De Wolf, Hans Papathanasopoulos, Maria A. Van Houtte, Margriet Stevens, Wendy S. de Wit, Tobias Rinke Stuyver, Lieven J. PLoS One Research Article To date, the majority of HIV-1 phenotypic resistance testing has been performed with subtype B virus backbones (e.g. HXB2). However, the relevance of using this backbone to determine resistance in non-subtype B HIV-1 viruses still needs to be assessed. From 114 HIV-1 subtype C clinical samples (36 ARV-naïve, 78 ARV-exposed), pol amplicons were produced and analyzed for phenotypic resistance using both a subtype B- and C-backbone in which the pol fragment was deleted. Phenotypic resistance was assessed in resulting recombinant virus stocks (RVS) for a series of antiretroviral drugs (ARV's) and expressed as fold change (FC), yielding 1660 FC comparisons. These Antivirogram® derived FC values were categorized as having resistant or sensitive susceptibility based on biological cut-off values (BCOs). The concordance between resistance calls obtained for the same clinical sample but derived from two different backbones (i.e. B and C) accounted for 86.1% (1429/1660) of the FC comparisons. However, when taking the assay variability into account, 95.8% (1590/1660) of the phenotypic data could be considered as being concordant with respect to their resistance call. No difference in the capacity to detect resistance associated with M184V, K103N and V106M mutations was noted between the two backbones. The following was concluded: (i) A high level of concordance was shown between the two backbone phenotypic resistance profiles; (ii) Assay variability is largely responsible for discordant results (i.e. for FC values close to BCO); (iii) Confidence intervals should be given around the BCO's, when assessing resistance in HIV-1 subtype C; (iv) No systematic resistance under- or overcalling of subtype C amplicons in the B-backbone was observed; (v) Virus backbone subtype sequence variability outside the pol region does not contribute to phenotypic FC values. In conclusion the HXB2 virus backbone remains an acceptable vector for phenotyping HIV-1 subtype C pol amplicons. Public Library of Science 2012-04-09 /pmc/articles/PMC3322145/ /pubmed/22496845 http://dx.doi.org/10.1371/journal.pone.0034708 Text en Bronze et al. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Bronze, Michelle
Steegen, Kim
Wallis, Carole L.
De Wolf, Hans
Papathanasopoulos, Maria A.
Van Houtte, Margriet
Stevens, Wendy S.
de Wit, Tobias Rinke
Stuyver, Lieven J.
HIV-1 Phenotypic Reverse Transcriptase Inhibitor Drug Resistance Test Interpretation Is Not Dependent on the Subtype of the Virus Backbone
title HIV-1 Phenotypic Reverse Transcriptase Inhibitor Drug Resistance Test Interpretation Is Not Dependent on the Subtype of the Virus Backbone
title_full HIV-1 Phenotypic Reverse Transcriptase Inhibitor Drug Resistance Test Interpretation Is Not Dependent on the Subtype of the Virus Backbone
title_fullStr HIV-1 Phenotypic Reverse Transcriptase Inhibitor Drug Resistance Test Interpretation Is Not Dependent on the Subtype of the Virus Backbone
title_full_unstemmed HIV-1 Phenotypic Reverse Transcriptase Inhibitor Drug Resistance Test Interpretation Is Not Dependent on the Subtype of the Virus Backbone
title_short HIV-1 Phenotypic Reverse Transcriptase Inhibitor Drug Resistance Test Interpretation Is Not Dependent on the Subtype of the Virus Backbone
title_sort hiv-1 phenotypic reverse transcriptase inhibitor drug resistance test interpretation is not dependent on the subtype of the virus backbone
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3322145/
https://www.ncbi.nlm.nih.gov/pubmed/22496845
http://dx.doi.org/10.1371/journal.pone.0034708
work_keys_str_mv AT bronzemichelle hiv1phenotypicreversetranscriptaseinhibitordrugresistancetestinterpretationisnotdependentonthesubtypeofthevirusbackbone
AT steegenkim hiv1phenotypicreversetranscriptaseinhibitordrugresistancetestinterpretationisnotdependentonthesubtypeofthevirusbackbone
AT walliscarolel hiv1phenotypicreversetranscriptaseinhibitordrugresistancetestinterpretationisnotdependentonthesubtypeofthevirusbackbone
AT dewolfhans hiv1phenotypicreversetranscriptaseinhibitordrugresistancetestinterpretationisnotdependentonthesubtypeofthevirusbackbone
AT papathanasopoulosmariaa hiv1phenotypicreversetranscriptaseinhibitordrugresistancetestinterpretationisnotdependentonthesubtypeofthevirusbackbone
AT vanhouttemargriet hiv1phenotypicreversetranscriptaseinhibitordrugresistancetestinterpretationisnotdependentonthesubtypeofthevirusbackbone
AT stevenswendys hiv1phenotypicreversetranscriptaseinhibitordrugresistancetestinterpretationisnotdependentonthesubtypeofthevirusbackbone
AT dewittobiasrinke hiv1phenotypicreversetranscriptaseinhibitordrugresistancetestinterpretationisnotdependentonthesubtypeofthevirusbackbone
AT stuyverlievenj hiv1phenotypicreversetranscriptaseinhibitordrugresistancetestinterpretationisnotdependentonthesubtypeofthevirusbackbone
AT hiv1phenotypicreversetranscriptaseinhibitordrugresistancetestinterpretationisnotdependentonthesubtypeofthevirusbackbone